Drug monitoring assay
AssigneeNovartis AG
InventorsPatrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Severine Marrony, Judith Schaefer
Life of this patent
Estimating the term…
Abstract
A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.
Claims4
A drug monitoring assay, comprising
- a) contacting a sample comprising at least one pharmaceutically active form of AEB071, as set forth in formula I
- with at least one antibody;
- and
- b) determining the concentration of said pharmaceutically active form of AEB071 in the sample,
- wherein the at least one antibody specifically binds the pharmaceutically active form of AEB071 with a higher specificity than at least one pharmaceutically inactive form of AEB071 and wherein said antibody also specifically binds a derivative of AEB071 selected from the group consisting of:
- (i) BJC, as set forth in formula II
- (ii) BJA, as set forth in formula III
A diagnostic kit for determining the concentration of at least one pharmaceutically active form of AEB071 in a sample, comprising at least one antibody that specifically binds at least one pharmaceutically active form of AEB071 with a higher specificity than a pharmaceutically inactive form of AEB071, and wherein said antibody also specifically binds a derivative of AEB071 selected from the group consisting of:
- (i) BJC, as set forth in formula (II)
- (ii) BJA, as set forth in formula (III)
Dependencies are inferred from the claim text.